(Press-News.org) UNSW Australia's solar researchers have converted over 40% of the sunlight hitting a solar system into electricity, the highest efficiency ever reported.
The record efficiency was achieved in outdoor tests in Sydney, before being independently confirmed by the National Renewable Energy Laboratory (NREL) at their outdoor test facility in the United States.
The work was funded by the Australian Renewable Energy Agency (ARENA) and supported by the Australia-US Institute for Advanced Photovoltaics (AUSIAPV).
"This is the highest efficiency ever reported for sunlight conversion into electricity," UNSW Scientia Professor and Director of the Advanced Centre for Advanced Photovoltaics (ACAP) Professor Martin Green said.
"We used commercial solar cells, but in a new way, so these efficiency improvements are readily accessible to the solar industry," added Dr Mark Keevers, the UNSW solar scientist who managed the project.
The 40% efficiency milestone is the latest in a long line of achievements by UNSW solar researchers spanning four decades. These include the first photovoltaic system to convert sunlight to electricity with over 20% efficiency in 1989, with the new result doubling this performance.
"The new results are based on the use of focused sunlight, and are particularly relevant to photovoltaic power towers being developed in Australia," Professor Green said.
Power towers are being developed by Australian company, RayGen Resources, which provided design and technical support for the high efficiency prototype. Another partner in the research was Spectrolab, a US-based company that provided some of the cells used in the project.
A key part of the prototype's design is the use of a custom optical bandpass filter to capture sunlight that is normally wasted by commercial solar cells on towers and convert it to electricity at a higher efficiency than the solar cells themselves ever could.
Such filters reflect particular wavelengths of light while transmitting others.
ARENA CEO Ivor Frischknecht said the achievement is another world first for Australian research and development and further demonstrates the value of investing in Australia's renewable energy ingenuity.
"We hope to see this home grown innovation take the next steps from prototyping to pilot scale demonstrations. Ultimately, more efficient commercial solar plants will make renewable energy cheaper, increasing its competitiveness."
The 40% efficiency achievement is outlined in a paper expected to be published soon by the Progress in Photovoltaics journal. It will also be presented at the Australian PV Institute's Asia-Pacific Solar Research Conference, which begins at UNSW today (Monday 8 December).
INFORMATION:
About UNSW Scientia Professor Martin Green:
Known as the 'Father of photovoltaics', Martin Green is a Scientia Professor at UNSW and Director of the Australian National Energy Agency-supported Centre for Advanced Photovoltaics. He was formerly a Director of CSG Solar, a company formed specifically to commercialise the University's thin-film, polycrystalline-silicon-on-glass solar cell. His group's contributions to photovoltaics are well known including the development of the world's highest efficiency silicon solar cells and the successes of several spin-off companies.
He is the author of six books on solar cells and numerous papers in the area of semiconductors, microelectronics, optoelectronics and, of course, solar cells. International awards include the 1999 Australia Prize, the 2002 Right Livelihood Award (also known as the Alternative Nobel Prize), the 2004 World Technology Award for Energy and the 2007 SolarWorld Einstein Award. He was elected into the prestigious Fellowship of the Royal Society in 2013. END
The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology (ASH) by researchers at Dana-Farber Cancer Institute.
The findings - to be presented in poster form on December 6, from 5:30 PM to 7:30 PM, in the West Building, Level 1 - may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma, the study authors say.
The study focused on ...
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. The personalized cell therapy reprograms a patient's immune system and offers the potential of long-term success.
"As we continue to follow children in this study, we see exciting results for ...
SAN FRANCISCO - A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology (ASH) in San Francisco.
The results provide some of the most dramatic evidence ...
SAN FRANCISCO, CA, December 6, 2014--In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders.
For Classical Hodgkin lymphoma (cHL) patients, two phase I studies are already demonstrating dramatic results. A study led by Craig H. Moskowitz, MD, Clinical ...
PHOENIX -- In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.
Their findings will be reported online Dec. 6 in the New England Journal of Medicine, and presented on Dec. 7 at the annual meeting of the American Society of Hematology (ASH), held in San Francisco.
Interim analysis of the ASPIRE clinical trial, which enrolled 792 patients with relapsed multiple myeloma ...
SAN FRANCISCO, CA, December 6, 2014--In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first time a study has demonstrated that adding a maintenance therapy after transplant can improve outcomes. The study, led by Craig H. Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society ...
COLUMBIA, Mo. - Unconventional oil and gas (UOG) operations combine directional drilling and hydraulic fracturing, or "fracking," to release natural gas from underground rock. Recent discussions have centered on potential air and water pollution from chemicals used in these processes and how it affects the more than 15 million Americans living within one mile of UOG operations. Now, Susan C. Nagel, a researcher with the University of Missouri, and national colleagues have conducted the largest review to date of research centered on fracking byproducts and their effects ...
Researchers from the University of Hawai'i (UH) and NOAA's Office of National Marine Sanctuaries today announced the discovery of an intact "ghost ship" in 2,000 feet of water nearly 20 miles off the coast of Oahu. Sitting upright, its solitary mast still standing and the ship's wheel still in place, the hulk of the former cable ship Dickenson, later the USS Kailua, was found on the seabed last year on a maritime heritage submersible mission with the UH Hawai'i Undersea Research Laboratory's (HURL) Terry Kerby and Drs. James Delgado and Hans Van Tilburg of the maritime ...
Cold Spring Harbor, NY - Scientists at Cold Spring Harbor Laboratory (CSHL) have devised a powerful algorithm that improves the effectiveness of an important research technology harnessing RNA interference, or RNAi.
Discovered in the late 1990s, RNAi is a naturally occurring biological mechanism in which short RNA molecules bind to and "interfere" with messages sent by genes that contain instructions for protein production. Such interference can prevent a gene from being expressed. In addition to helping regulate gene expression, the RNAi pathway in many species, ...
LA JOLLA-Pain typically has a clear cause-but not always. When a person touches something hot or bumps into a sharp object, it's no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.
In a major breakthrough, a team led by researchers at the Salk Institute and Harvard Medical School have identified an important neural mechanism in the spinal cord that appears to be capable of sending erroneous pain signals to the brain.
By charting the spinal circuits that process ...
